DUBLIN – Proteros Biostructures GmbH could bank up to $126 million in up-front and research funding, as well as milestone payments, from a drug discovery deal with Merck & Co. focused on an undisclosed epigenetic cancer target. The deal also involves tiered royalties on product sales.